Shirin Moshiri Gulledge alias The Spine-to-Supplement Shuttle

Shirin Moshiri Gulledge is not licensed or approved by Kansas State Board of Healing Arts (Chiropractic) to diagnose, treat, or cure headaches or migraines.

headaches or migraines

Supports

The indexed BMJ systematic review and network meta-analysis shows that multiple licensed oral drugs (including triptans and NSAIDs) are effective for the acute treatment of migraine episodes in adults, improving pain freedom at two hours and sustained pain freedom to 24 hours. ^{[1][5][6][7][8]} This provides strong RCT-based evidence that pharmacologic treatment can meaningfully reduce migraine headache symptoms. The systematic review and meta-analysis on vitamin B2 (riboflavin) prophylaxis finds that 400 mg/day for three months significantly reduces the days, duration, frequency, and pain scores of migraine attacks, supporting a role for certain nutritional interventions in reducing migraine burden. ^[3] The epidemiologic systematic review and meta-analysis in children and adolescents confirms that primary headaches, including migraine, are common and clinically significant in younger populations, reinforcing that headaches/migraines are recognized medical conditions with substantial prevalence and impact. ^[4] Current guideline-driven management of hypertension discusses blood pressure control as part of broader cardiovascular risk reduction, and while not focused on migraine, it aligns with mainstream guidance that vascular risk factors are medically important in patients with migraine with aura. ^[2]

Contradicts

None of the indexed high-quality papers suggest that headaches or migraines are trivial or not real conditions; instead, they consistently treat migraine as a significant neurologic disorder requiring evidence-based management. ^[2] The BMJ network meta-analysis emphasizes that some newer agents (lasmiditan, rimegepant, ubrogepant) are less efficacious than the best-performing triptans, contradicting any blanket claim that newer drugs are universally superior for migraine headaches. ^{[1][5][6][7][8]} The vitamin B2 meta-analysis, while supportive of benefit, is based on a limited number of trials and therefore does not justify overinflated claims that riboflavin alone will cure migraines; the evidence supports modest prophylactic benefit rather than complete resolution. ^[3] The epidemiology review shows high prevalence but does not support claims that all headaches are migraines or that a single mechanism or treatment applies universally across headache types; tension-type and other primary headaches remain distinct entities. ^[4]

Mainstream view

Mainstream medical and scientific consensus is that migraine is a common, disabling primary headache disorder with characteristic features (e. g. , throbbing pain, nausea, photophobia), distinct from other headache types such as tension-type headache. Evidence-based management involves both acute treatments (triptans, NSAIDs, gepants, ditans, and combination regimens) and preventive strategies (pharmacologic prophylaxis, selected supplements such as riboflavin, lifestyle modification), chosen according to disease severity, comorbidities, and patient preference. ^[2] Large network meta-analyses indicate that certain triptans (particularly eletriptan, rizatriptan, sumatriptan, and zolmitriptan) have the most favorable balance of efficacy and tolerability for acute migraine episodes, and are generally preferred first-line agents in adults without high cardiovascular risk. ^{[1][3][5][6][7][8]} Preventive measures such as vitamin B2 have supportive but not definitive evidence, and are usually considered adjuncts within a broader prophylactic strategy rather than stand-alone cures. Epidemiologic data support that primary headaches and migraines are prevalent across the lifespan, including in children and adolescents, and merit structured assessment and management rather than dismissal as minor complaints. ^[4] Deterministic PubMed cross-check found no matching indexed studies for these terms (absence of indexed evidence is not evidence against the claim).

In their own wordsView sourceArchived copy

“HEADACHES OR MIGRAINES?”

Rule: K.S.A. §65-2871 (Kansas Healing Arts Act)

Shirin Moshiri Gulledge is not licensed or approved by Kansas State Board of Healing Arts (Chiropractic) to diagnose, treat, or cure carpal tunnel.

carpal tunnel

Supports

Carpal tunnel syndrome is a recognized clinical condition with substantial peer-reviewed literature on diagnosis and treatment, including systematic reviews comparing local corticosteroid injection with surgical release and reviews on diagnostic association with carpal tunnel cross-sectional area . These reviews support that carpal tunnel syndrome can be assessed and treated using evidence-based approaches, and that ultrasound-derived cross-sectional area has diagnostic value, although the exact strength varies by study design and threshold .

Contradicts

The claim as written is too vague to evaluate as a substantive medical statement, because it only names a condition and does not make an actionable or testable assertion. The provided index papers do not establish any specific claim about prevention, cure, causation, or a particular treatment for carpal tunnel syndrome. The dentist-prevalence review is about prevalence in a specific occupational group and does not generalize to all patients, and the peer-review records do not add clinical evidence . Evidence comparing steroid injection with surgery addresses treatment options rather than proving one universally superior approach for all cases, so broad influencer-style claims about a single best remedy would be unsupported or overgeneralized .

Mainstream view

Mainstream medical consensus is that carpal tunnel syndrome is a common entrapment neuropathy diagnosed clinically, sometimes supported by electrodiagnostic testing or ultrasound, and managed with splinting, corticosteroid injection, activity modification, and surgical release for persistent or severe cases. High-quality reviews support corticosteroid injection as a short-term option and surgery as an effective definitive treatment for appropriate patients, while no single non-surgical approach is universally curative. Because the user-supplied claim is only the phrase carpal tunnel, there is no specific factual assertion to confirm or refute.

In their own wordsView sourceArchived copy

“CARPAL TUNNEL?”

Rule: K.S.A. §65-2871 (Kansas Healing Arts Act)

Shirin Moshiri Gulledge is not licensed or approved by Kansas State Board of Healing Arts (Chiropractic) to diagnose, treat, or cure weight loss services.

weight loss services

Supports

The general concept of professional weight loss services that include structured lifestyle interventions, pharmacologic therapy, and (in selected cases) bariatric surgery is strongly supported by multiple high‑quality guidelines and systematic reviews. Intensive, multicomponent behavioral interventions for adults with BMI ≥30 kg/m² are recommended by major guideline bodies as effective for clinically meaningful weight loss and risk factor improvement, consistent with the US Preventive Services Task Force statement that clinicians should offer or refer such adults to intensive behavioral programs.^[15] Lifestyle modification (diet, physical activity, behavioral therapy) is consistently described as the cornerstone of obesity management, with pharmacologic and sometimes surgical approaches used as adjuncts when lifestyle alone is insufficient.^{[11][12][16][18][19]} Contemporary guidelines from organizations such as the American College of Physicians, gastroenterology and obesity societies recommend evidence‑based anti‑obesity medications (e.g., GLP‑1 receptor agonists like semaglutide, dual incretin agonists like tirzepatide, and other agents) for adults with BMI ≥30 or ≥27 with comorbidities who fail lifestyle interventions, showing clinically meaningful and often substantial weight loss and cardiometabolic benefit.^{[8][9][12][13][14][16][18][19]} Bariatric surgery is endorsed as the most effective long‑term option for severe obesity when combined with lifestyle and, in some cases, pharmacotherapy, supported by clinical practice guidelines and reviews focusing on specific populations such as menopausal women and adolescents.^[3][4][17] Overall, there is strong evidence that medically supervised, guideline‑driven weight loss services improve weight, metabolic risk factors, and obesity‑related health outcomes and should be delivered using a structured, person‑centered, multidisciplinary approach.^{[5][6][9][16][18][19]}

Contradicts

While weight loss services are broadly supported, evidence and guidelines also highlight important limitations that contradict overly simplistic or universal claims. Guidelines emphasize that lifestyle programs alone often have limited long‑term effectiveness and durability for many people, with modest average weight loss and common weight regain, so services that promise dramatic or permanent weight loss from lifestyle change alone are not well supported.^[5][16][18] Pharmacologic weight loss services are recommended only for clearly defined indications (BMI thresholds and comorbidities) and must be used as adjuncts to lifestyle, not as stand‑alone quick fixes; guideline panels note concerns about side effects, cost, access, adherence, and weight regain after discontinuation, which contradict marketing that portrays medications as risk‑free or one‑time cures.^{[5][8][9][12][14][17][18][19]} Some drugs historically used for weight loss have limited evidence or safety concerns, and high‑quality guidelines explicitly recommend against or restrict certain agents (e.g., orlistat or compounded/unsupported preparations), so services that rely on non‑approved, compounded, or poorly studied medications fall outside evidence‑based practice.^{[9][14][17][19]} Evidence is weaker or lacking in specific populations, such as adolescents after bariatric surgery, where systematic reviews report a paucity of data on pharmacotherapy in this subgroup, limiting strong claims about the effectiveness of such combined services.^[4] Overall, the literature contradicts any claim that generic “weight loss services” are uniformly effective or appropriate for everyone; effectiveness depends on intensity, modality, adherence, appropriate patient selection, and long‑term follow‑up, and any service that ignores these constraints is not evidence‑based.^{[5][9][15][16][18][19]}

Mainstream view

The mainstream medical position is that obesity is a chronic, relapsing disease requiring long‑term, structured management, and that evidence‑based weight loss services should be multidisciplinary, guideline‑driven, and tailored to individual risk and preferences. Standard care begins with intensive lifestyle interventions—dietary change, increased physical activity, and behavioral therapy—as the foundation of treatment, delivered through structured programs for patients with obesity and often provided via specialized weight management services.^{[11][12][15][16][19]} When lifestyle measures alone do not achieve clinically meaningful weight loss (typically ≥5% of baseline weight), current guidelines support adding approved anti‑obesity pharmacotherapy for adults meeting BMI and comorbidity criteria, with GLP‑1 and dual GIP/GLP‑1 agonists now considered first‑line agents in many guidelines because of their superior efficacy and cardiometabolic benefits.^{[8][9][12][13][14][16][18][19]} Bariatric surgery is recognized as the most effective intervention for severe obesity, but it is reserved for selected patients and integrated into broader services

In their own wordsView sourceArchived copy

“we offer chiropractic, spinal rehabilitation, acupuncture, and weight loss services”

Rule: K.S.A. §65-2871 (Kansas Healing Arts Act)